» Articles » PMID: 36370118

Effects of Chronic Cirrhosis Induced by Intraperitoneal Thioacetamide Injection on the Protein Content and Michaelis-Menten Kinetics of Cytochrome P450 Enzymes in the Rat Liver Microsomes

Overview
Specialties Pharmacology
Toxicology
Date 2022 Nov 12
PMID 36370118
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic intraperitoneal injection of thioacetamide (TAA) in rats has been used as an animal model of human cirrhosis to study the effects of the disease on drug metabolism. However, TAA inhibits P450 enzymes directly and independently of cirrhosis. We investigated the effects of chronic cirrhosis in rats, induced by 10 weeks of intraperitoneal TAA, on the P450 enzymes after a 10-day washout period to eliminate TAA. Liver histology and serum biomarkers of hepatic function confirmed cirrhosis in all animals. Microsomal total P450 content, P450 reductase activity and ethoxycoumarin O-deethylase activity, a general marker of P450 activity, were significantly reduced by 30%-50% in cirrhotic animals. Additionally, the protein content and Michaelis-Menten kinetics of the activities of CYP2D, CYP2E1 and CYP3A were investigated. Whereas cirrhosis reduced the microsomal protein contents of CYP2D and CYP3A by 70% and 30%, respectively, the protein contents of CYP2E1 were not affected. However, the activities of all the tested isoenzymes were substantially lower in the cirrhotic livers. It is concluded that the TAA model of cirrhosis that incorporates a 10-day washout period after intraperitoneal injection of the chemical to rats produces isoenzyme-selective reductions in the P450 proteins or activities, which are independent of the direct inhibitory effects of TAA.

Citing Articles

Bile duct ligation-induced cirrhosis does not alter the blood-brain barrier permeability to sucrose in rats.

Miah M, Bickel U, Mehvar R Metab Brain Dis. 2024; 40(1):53.

PMID: 39636464 PMC: 11621172. DOI: 10.1007/s11011-024-01486-6.


Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.


Generation and Characterization of CYP2E1-Overexpressing HepG2 Cells to Study the Role of CYP2E1 in Hepatic Hypoxia-Reoxygenation Injury.

Alwadei N, Rashid M, Chandrashekar D, Rahighi S, Totonchy J, Sharma A Int J Mol Sci. 2023; 24(9).

PMID: 37175827 PMC: 10179595. DOI: 10.3390/ijms24098121.


Effects of chronic cirrhosis induced by intraperitoneal thioacetamide injection on the protein content and Michaelis-Menten kinetics of cytochrome P450 enzymes in the rat liver microsomes.

Chandrashekar D, DuBois B, Rashid M, Mehvar R Basic Clin Pharmacol Toxicol. 2022; 132(2):197-210.

PMID: 36370118 PMC: 10100077. DOI: 10.1111/bcpt.13813.

References
1.
Walsky R, Obach R . Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(6):647-60. DOI: 10.1124/dmd.32.6.647. View

2.
Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J . CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2013; 77(1):160-9. PMC: 3895357. DOI: 10.1111/bcp.12182. View

3.
Wallace M, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P . Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim. 2015; 49(1 Suppl):21-9. DOI: 10.1177/0023677215573040. View

4.
Bastien M, Leblond F, Pichette V, Villeneuve J . Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can J Physiol Pharmacol. 2000; 78(11):912-9. View

5.
Oe S, Fukunaka Y, Hirose T, Yamaoka Y, Tabata Y . A trial on regeneration therapy of rat liver cirrhosis by controlled release of hepatocyte growth factor. J Control Release. 2003; 88(2):193-200. DOI: 10.1016/s0168-3659(02)00463-7. View